Development of neutralizing antibodies against biotherapeutic agents administered to
prevent or treat various clinical conditions is a longstanding and growing problem faced by …

The development of neutralizing antibodies in hemophilia is a serious complication of factor
replacement therapy. These antibodies, also known as “inhibitors”, significantly increase …

Frequent infusions of intravenous factor VIII (FVIII) are required to prevent bleeding
associated with hemophilia A. To reduce the treatment burden, recombinant FVIII with a …

Interaction of factor VIII (FVIII) with von Willebrand factor (VWF) is mediated by the VWF D′
D3 domains and thrombin-mediated release is essential for hemostasis after vascular injury …

Inhibitor formation in hemophilia A is the most feared treatment-related complication of factor
VIII (fVIII) therapy. Most inhibitor patients with hemophilia A develop antibodies against the …

Background Standard chemotherapy with taxanes, such as paclitaxel (PTX), remains the
mainstay of systemic treatment of triple-negative breast cancer. Nanotechnology-based …

The development of inhibitory antibodies to therapeutic factor VIII is the major complication
of replacement therapy in patients with hemophilia A. The first step in the initiation of the anti …

A major problem in treating hemophilia A patients with therapeutic factor VIII (FVIII) is that
20% to 30% of these patients produce neutralizing anti-FVIII antibodies. These antibodies …

It has been proposed that von Willebrand factor might affect factor VIII immunogenicity by
reducing factor VIII uptake by antigen presenting cells. Here we investigate the interaction of …

Antibody inhibitor development in hemophilia A represents the most significant complication
resulting from factor VIII (fVIII) replacement therapy. Recent studies have demonstrated that …